United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA on the 2

U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer's Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older

BioNTech SE

The FDA says the Pfizer Covid vaccine is both safe and effective. CNBC spoke with Pfizer and Moderna trial participants about what side effects you can expect.

The FDA says Pfizer's Covid vaccine is safe and effective. But brace yourself for the second shot, trial participants warn

Baidu

Altria

Teekay Tankers

These bargain stocks could potentially outperform in the coming year. They have strong fundamentals and are worth holding long-term as well.

4 Undervalued Bargain Stocks to Buy Before They Bounce

An all-day regulatory meeting scheduled to take place Thursday is the next step toward the likely authorization of the first COVID-19 vaccine in the U.S.

U.S. inches closer to FDA authorization of first COVID-19 vaccine

The White House on Tuesday claimed that Pfizer is “negotiating in public” on the allocation of the forthcoming coronavirus vaccine and trying to embarrass the U.S. government in an effort to gain market share over its vaccine competitors.

White House claims Pfizer 'negotiating in public' on coronavirus vaccine allocation

Pfizer stock eked out a small gain Tuesday after Food and Drug Administration documents appeared to support authorizing its coronavirus vaccine. An advisory committee will meet Thursday.

Pfizer Stock Rallies As FDA Appears To Support Covid Vaccine Approval

Pfizer Chief Executive Albert Bourla said on Tuesday he expects a "very intense" meeting with a U.S. vaccine advisory panel this week but is counting on the panel of outside experts to sign off on his company's COVID-19 vaccine candidate.

Pfizer CEO confident of getting U.S. advisory panel nod for COVID-19 vaccine

Ninety-year-old Margaret Keenan on Tuesday became the first person in the world to receive the Pfizer-BioNTech vaccine outside of trial conditions.

UK begins rollout of Pfizer's coronavirus vaccine: Here's what you need to know

That conclusion is based on a new, unfiltered look at clinical trial data from the BNT162b2 program.

Pfizer's Coronavirus Vaccine Is 52.4% Effective After First Dose

The COVID-19 vaccine candidate developed by BioNTech and Pfizer Inc. likely has a "favorable safety profile," according to documents published Tuesday by the Food and Drug Administration. In premarket trading on Tuesday, BioNTech's stock was up 1.3%, and shares of Pfizer gained 0.9%.

FDA highlights safety profile of BioNTech/Pfizer vaccine in advance of advisory committee meeting

WASHINGTON (AP) — Documents released by U.S. regulators Tuesday confirmed that Pfizer and BioNTech's COVID-19 vaccine was strongly protective against COVID-19 -- offering the world's first detailed look at the evidence behind the shots.

Pfizer's COVID-19 vaccine data gets positive FDA review

Here's what you need to know about the impact of Covid-19 to navigate the markets today.

FDA Analysis Confirms Safety of Pfizer Vaccine

Moderna

Teladoc

10X Genomics

Veeva Systems

Here's how these big businesses became enormous during a year most of us would rather forget.

These 5 Large-Cap Healthcare Stocks Had the Best Gains in 2020

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is now approved for emergency use in United Kingdom and Bahrain.

Pfizer (PFE) Up 14% in 3 Months on COVID-19 Vaccine Progress

"Pfizer did offer up an additional allotment ... to the United States government multiple times," Dr. Scott Gottlieb told CNBC.

U.S. declined Pfizer offer for additional Covid vaccine doses, says board member Dr. Scott Gottlieb

The Food and Drug Administration said Tuesday data from Pfizer's coronavirus vaccine trials did not raise any specific safety concerns.

FDA says Pfizer Covid vaccine data did not raise safety concerns.

The Food and Drug Administration is reportedly expected to release detailed data about Pfizer's coronavirus vaccine on Tuesday as regulators consider whether to clear it for emergency use. The data will give the public an in-depth look at how well the vaccine works before the FDA's vaccine committee meets Thursday to consider Pfizer's application for.

FDA to release detailed data on Pfizer's COVID-19 vaccine

The latest IBD/TIPP Poll shows just 52% of Americans are likely to get a coronavirus vaccine — a fact that could hamstring Pfizer and Moderna, the makers of the two front-running drugs. The post Pfizer, Moderna Face Public-Relations Hurdle For Covid Vaccines: IBD/TIPP Poll appeared first on Investor's Business Daily.

Pfizer, Moderna Face Public-Relations Hurdle For Covid Vaccines: IBD/TIPP Poll

Experts maintain that widespread rollout of these vaccines, which have undergone rigorous testing, is very likely to be safe.

No, the Pfizer and Moderna vaccine development has not been ‘reckless.'

The U.K. will receive just 4 million doses of the vaccine being developed by AstraZeneca and the University of Oxford — by year-end — short of the 30 million doses hoped for.

World watches as first person receives Pfizer-BioNTech COVID shot

The UK is the first country to approve Pfizer's vaccine and is beginning its rollout on Tuesday.

COVID-19 vaccine: 90-year-old woman becomes first to receive Pfizer vaccine in UK

AbbVie

Merck

Healthcare stocks are a staple of every portfolio. With an ageing population, healthcare stocks are here to stay.

Pfizer Vs. Merck Vs. AbbVie Vs.

AstraZeneca

The United Kingdom will administer one shot each of COVID-19 vaccines made by Pfizer Inc (NYSE: PFE) and AstraZeneca plc (NASDAQ: AZN) to test whether the approach would result in increased immunity, Bloomberg reported Monday. What Happened: The studies planned for the next year, will be “relatively small” as per Clive Dix, Deputy Chair of U.K. Vaccine Taskforce, who added — “They'll only be with the approved vaccines.

Pfizer, AstraZeneca Vaccine Combination To Be Tested Against COVID-19 In UK

Pfizer Inc (NYSE: PFE) has told the outgoing Donald Trump administration that it cannot supply a considerable amount of additional doses of its COVID-19 vaccine to the United States until late June because other countries have hastened to secure the supply, the Washington Post reported Monday. What Happened: The development means that the U.S. government may have difficulty in procurement beyond the 100 million doses it has already secured earlier this year, according to the Post.

Pfizer Tells US It Can't Provide Substantial Extra Doses Before June As Other Countries Have Already Secured Supply: WaPo

A member of a United States Food and Drug Administration committee on vaccines said that the agency could issue an emergency authorization for Pfizer Inc's (NYSE: PFE) COVID-19 vaccine as early as Friday. What Happened: James Hildreth, a member of the Vaccines and Related Biological Products Advisory Committee, said on NBC's “Weekend Today” show that the body would meet on Thursday to review the COVID-19 vaccine developed by Pfizer and its German partner BioNTech SE (NASDAQ: BNTX).

News for Pfizer Stock (PFE)